<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03415152</url>
  </required_header>
  <id_info>
    <org_study_id>PUFA5004</org_study_id>
    <nct_id>NCT03415152</nct_id>
  </id_info>
  <brief_title>A Prospective Observational Program Using Digital Technology Tools to Enhance Patient Adherence to Omacor Therapy</brief_title>
  <acronym>DIAPAsOn</acronym>
  <official_title>A Prospective Observational Program Using Digital Technology Tools to Enhance Patient Adherence to Omacor Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective observational program using digital technology tools to enhance patient&#xD;
      adherence to Omacor therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is known that only 50% of patients with chronic diseases adhere to medical&#xD;
      recommendations; at the same time, high patient adherence significantly improve the survival&#xD;
      of patients with chronic diseases. The treatment duration required to achieve a significant&#xD;
      reduction in the risk of cardiovascular complications is the subject of discussion, but&#xD;
      studies demonstrate that long-term therapy for 5 years or more gives the greatest effect.&#xD;
      Today, during the era of technological progress, there is a possibility to freely apply&#xD;
      information and telecommunication technologies (e.g. cell phones, computer) in different&#xD;
      fields, including medicine. Remote monitoring of patients by means of phone calls using&#xD;
      structured questionnaires can also significantly improve clinical outcomes (mortality and&#xD;
      cardiovascular hospitalizations) by 38%. Unfortunately, in the case of a long-term, usually&#xD;
      lifetime, treatment, the use of such methods is still very limited on a large scale.&#xD;
&#xD;
      This prospective observational program will help to explore the use of digital technologies&#xD;
      and evaluate their effectiveness to increase patient adherence using an example of patients&#xD;
      whose treatment scheme includes Omacor. Physicians and patients will be granted a personal&#xD;
      access to the electronic data capture system. The physician will enter data about patients&#xD;
      who signed the informed consent into the electronic system. At Visit 1 the patient will be&#xD;
      given a card providing the personal access to his/her account in the electronic system. In&#xD;
      addition to visits to the physician, the program specifies remote completion of the&#xD;
      electronic form by the patient. Additional objective of the program includes raising&#xD;
      patients' awareness about the disease due to familiarization with educational materials&#xD;
      available in patient personal account in the electronic system.&#xD;
&#xD;
      This study is a prospective observational program within the frames of which Omacor (Omega-3&#xD;
      triglycerides [EPA/docosahexaenoic acid (DHA) = 1.2/1 - 90%]) is prescribed to patients with&#xD;
      a history of myocardial infarction within a routine procedure as a part of the combination&#xD;
      therapy (in combination with statins, antiaggregants, beta-blockers, angiotensin-converting&#xD;
      enzyme inhibitors (ACE)) and/or to patients with hypertriglyceridemia. The population of&#xD;
      observed patients will be limited to those who were prescribed Omacor for the first time or&#xD;
      not earlier than 3 months after the last dose of Omacor and course of administration is at&#xD;
      least 6 months. Discontinuation of the drug product administration by the patient is not the&#xD;
      reason for exclusion of the patient from the study. For outcome measures which are&#xD;
      applicable, further analysis will be performed in subgroups of patients with the different&#xD;
      medication adherence rate: &lt;0,5, 0,5-0,7, ≥0,8 at Visit 2 and Visit 3. Adherence rate will be&#xD;
      calculated as the sum of days when patient taken the full prescribed dose of Omacor in period&#xD;
      divided by the number of days in period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 24, 2018</start_date>
  <completion_date type="Actual">July 1, 2019</completion_date>
  <primary_completion_date type="Actual">July 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Adherence Rate at the End of the Study (Visit 3)</measure>
    <time_frame>6 months</time_frame>
    <description>Mean adherence rate is a ratio of the sum of days when the patient took the full prescribed dose of Omacor in the specified period to the number of days in the period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Score of National Questionnaire of Treatment Compliance (Edited by Fofanova T.V. et al.) at the End of the Study (Visit 3)</measure>
    <time_frame>6 months</time_frame>
    <description>The average score for the National questionnaire on therapy compliance for all study duration Visit 1 - Visit 3.&#xD;
The text of the National questionnaire of treatment compliance consists of five statements with four options for choice. The answer corresponding to very high compliance is estimated at 3 points, the answer corresponding to high compliance is estimated at 2 points, medium compliance - at 1 point and low compliance - 0 points. The patient can get a maximum of 15 points, a minimum of 0 points. Higher scores mean higher compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Patients Who Have Chosen Each of the Suggested Reasons for Therapy Termination</measure>
    <time_frame>6 months</time_frame>
    <description>The percentage of patients (%) who have chosen each of the suggested reason for therapy termination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Average Score on Each of 8 Scales of Short Form Survey (SF)-36 Quality of Life Questionnaire at Visit 2 and Visit 3 vs. the Baseline (Visit 1)</measure>
    <time_frame>3 months, 6 months</time_frame>
    <description>Mean difference of the average score on each of 8 scales of Short Form Survey (SF)-36 quality of life questionnaire at Visit 2 and Visit 3 versus the baseline.&#xD;
36-Item Short Form Survey (SF-36) taps eight health concepts. Each of 36 items is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively, so that a high score defines a more favorable health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Lipid Profile Parameters at Visit 2 and Visit 3 vs. the Baseline (Visit 1)</measure>
    <time_frame>3 months, 6 months</time_frame>
    <description>Mean difference of lipid profile parameters at Visit 2 and Visit 3 vs. the Baseline (Visit&#xD;
1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalizations Due to Cardio-vascular Reasons During 6 Months of the Program</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of patients with hospitalizations due to cardiovascular disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of New Cases of Stenocardia During 6 Months of the Program</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of patients with new cases of stenocardia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Non-fatal Myocardial Infarction Cases During 6 Months of the Program</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of patients with non-fatal myocardial infarction cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cases of Cardio-vascular Death During 6 Months of the Program</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of patients dead due to cardio-vascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Adherence Rate at Visit 2</measure>
    <time_frame>3 months</time_frame>
    <description>Mean adherence rate is a ratio of the sum of days when the patient took the full prescribed dose of Omacor in the specified period to the number of days in the period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Mean Adherence Rate by End of the Study (Visit 3) Versus Visit 2</measure>
    <time_frame>3 months, 6 months</time_frame>
    <description>Mean adherence rate is a ratio of the sum of days when the patient took the full prescribed dose of Omacor in the specified period to the number of days in the period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Patients With Adherence Rate &lt;0,5, 0,5-0,7, ≥0,8 at Visit 2 and Visit 3</measure>
    <time_frame>3 months, 6 months</time_frame>
    <description>The percentage of patients with adherence rate &lt;0,5, 0,5-0,7, ≥0,8 at Visit 2 and Visit 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Score of National Questionnaire of Treatment Compliance (Edited by Fofanova T.V. et al.) [9] at Visit 1, Visit 2</measure>
    <time_frame>0 months, 3 months</time_frame>
    <description>The average score for the National questionnaire on therapy compliance at Visit 1, Visit 2.&#xD;
The text of the National questionnaire of treatment compliance consists of five statements with four options for choice. The answer corresponding to very high compliance is estimated at 3 points, the answer corresponding to high compliance is estimated at 2 points, medium compliance - at 1 point and low compliance - 0 points. The patient can get a maximum of 15 points, a minimum of 0 points. Higher scores mean higher compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Mean Score of National Questionnaire of Treatment Compliance (Edited by Fofanova T.V. et al.) [9] at Visit 2 and Visit 3 Versus Baseline (Visit 1)</measure>
    <time_frame>Baseline, 3 Months, 6 Months</time_frame>
    <description>The text of the National questionnaire of treatment compliance consists of five statements with four options for choice. The answer corresponding to very high compliance is estimated at 3 points, the answer corresponding to high compliance is estimated at 2 points, medium compliance - at 1 point and low compliance - 0 points. The patient can get a maximum of 15 points, a minimum of 0 points.&#xD;
Higher scores mean higher compliance</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3000</enrollment>
  <condition>History of Myocardial Infarction</condition>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Omacor (Omega-3-acid ethyl esters)</arm_group_label>
    <description>Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who having been prescribed Omacor for at least 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omacor (Omega-3-acid ethyl esters)</intervention_name>
    <description>Observational study without intervention, Omacor is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.</description>
    <arm_group_label>Omacor (Omega-3-acid ethyl esters)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with myocardial infarction in anamnesis and/or diagnosis of&#xD;
        hypertriglyceridemia who are under medical supervision in healthcare institutions of Russia&#xD;
        and receive Omacor&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women ≥ 18 years of age&#xD;
&#xD;
          -  Patients with history of myocardial infarction not earlier than 6 months ago. AND/OR&#xD;
             Patients with diagnosis of hypertriglyceridemia&#xD;
&#xD;
          -  Patients having been prescribed Omacor (Omega-3 triglycerides [EPA/DHA = 1.2/1 - 90%])&#xD;
             for at least 6 months AND who have been taking Omacor no more than 14 days at the time&#xD;
             of enrollment into the program.&#xD;
&#xD;
          -  Patients who can, in the opinion of the Investigator, himself or through immediate&#xD;
             relatives's help complete electronic system of data collection through mobile&#xD;
             application or web-browser&#xD;
&#xD;
          -  Patients who have signed the consent to participate in this program before entering&#xD;
             their data in the electronic Case Report Form (eCRF) and who understand their right to&#xD;
             discontinue the program at any time&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients taken medicines (except for Omacor) or nutrition supplements containing&#xD;
             omega-3 in any proportions at the time of enrollment into the program OR it has been&#xD;
             less than 3 months since last dose of medicines or nutrition supplements containing&#xD;
             omega-3 taken.&#xD;
&#xD;
          -  Female patients during pregnancy or breastfeeding&#xD;
&#xD;
          -  Patients with increased sensitivity to the active substance, excipients, and soy&#xD;
&#xD;
          -  Patients with exogenous hypertriglyceridemia (type I hyperchylomicronemia)&#xD;
&#xD;
          -  Participation in any other clinical or non-clinical study/program at present or within&#xD;
             the latest 30 days&#xD;
&#xD;
          -  Patients with any other clinical states that make him/her ineligible for the program&#xD;
             on the study doctor's opinion based on clinical assessment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gbuz Amokb Jsc</name>
      <address>
        <city>Astrakhan</city>
        <zip>414056</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>polyclinic GKB №21</name>
      <address>
        <city>Bashkortostan</city>
        <zip>450071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GAUZ &quot;BKDTs&quot;</name>
      <address>
        <city>Bryansk</city>
        <zip>241050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GP # 1</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GKB №3</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution &quot;Research Institute of Complex Problems of Cardiovascular Diseases&quot;</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBUZ Polyclinic of City Clinical Hospital № 10</name>
      <address>
        <city>Khabarovsk</city>
        <zip>680000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GP #2</name>
      <address>
        <city>Krasnodar</city>
        <zip>350000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBUZ GP number 11</name>
      <address>
        <city>Krasnodar</city>
        <zip>350000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gbuz Kkb #2</name>
      <address>
        <city>Krasnodar</city>
        <zip>350012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBUZ Regional clinical hospital № 2</name>
      <address>
        <city>Krasnodar</city>
        <zip>350012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yablonovskaya polyclinic</name>
      <address>
        <city>Krasnodar</city>
        <zip>350049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KKB #1</name>
      <address>
        <city>Krasnodar</city>
        <zip>350059</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Polyclinic №27</name>
      <address>
        <city>Krasnodar</city>
        <zip>350061</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GP №27</name>
      <address>
        <city>Krasnodar</city>
        <zip>350061</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Llc &quot;Auris&quot;</name>
      <address>
        <city>Krasnodar</city>
        <zip>350061</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Polyclinic №7</name>
      <address>
        <city>Krasnodar</city>
        <zip>350063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic Mamme</name>
      <address>
        <city>Krasnodar</city>
        <zip>350075</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GP №15</name>
      <address>
        <city>Krasnodar</city>
        <zip>350075</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GP №17</name>
      <address>
        <city>Krasnodar</city>
        <zip>350080</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mbuz Gp #17</name>
      <address>
        <city>Krasnodar</city>
        <zip>350080</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gbuz Nii Kkb №1</name>
      <address>
        <city>Krasnodar</city>
        <zip>350086</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gbuz &quot;Nii-Kkb №1&quot;</name>
      <address>
        <city>Krasnodar</city>
        <zip>350087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GP №25</name>
      <address>
        <city>Krasnodar</city>
        <zip>350089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBUZ City Polyclinic #11</name>
      <address>
        <city>Krasnodar</city>
        <zip>350910</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal budgetary health institution &quot;City Polyclinic # 11&quot;</name>
      <address>
        <city>Krasnodar</city>
        <zip>350911</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mbuz Gkb №1</name>
      <address>
        <city>Krasnodar</city>
        <zip>350915</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC Ultramed</name>
      <address>
        <city>Krasnodar</city>
        <zip>350915</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUZ Polyclinic TsRB Poltava</name>
      <address>
        <city>Krasnodar</city>
        <zip>353800</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Modern Cardiology&quot;</name>
      <address>
        <city>Krasnodar</city>
        <zip>353925</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic &quot;Medicine for All&quot;</name>
      <address>
        <city>Krasnodar</city>
        <zip>385141</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinic № 1</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maikop City Polyclinic №1</name>
      <address>
        <city>Maykop</city>
        <zip>385018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinic №52 branch №1</name>
      <address>
        <city>Moscow</city>
        <zip>115404</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ГП № 210 branch 2</name>
      <address>
        <city>Moscow</city>
        <zip>115408</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FGBU Federal Clinical Research Centre of Russia's Federal Medical-Biological Agency</name>
      <address>
        <city>Moscow</city>
        <zip>115682</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gbuz &quot;Gp #22 Dzm&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>117218</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fsbi Enc Mz Rf</name>
      <address>
        <city>Moscow</city>
        <zip>117292</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City polyclinic № 22</name>
      <address>
        <city>Moscow</city>
        <zip>117418</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GP number 176</name>
      <address>
        <city>Moscow</city>
        <zip>117463</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Clinical Center №1</name>
      <address>
        <city>Moscow</city>
        <zip>117647</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OOO &quot;Lechebnii center&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>119034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City polyclinic № 195</name>
      <address>
        <city>Moscow</city>
        <zip>121609</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Outpatient center of CDC #4</name>
      <address>
        <city>Moscow</city>
        <zip>121609</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GP №45</name>
      <address>
        <city>Moscow</city>
        <zip>12517</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBUZ City polyclinic # 43 DZM filial #3</name>
      <address>
        <city>Moscow</city>
        <zip>125446</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GP №219 branch №4</name>
      <address>
        <city>Moscow</city>
        <zip>125466</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Branch №1 DGP #94</name>
      <address>
        <city>Moscow</city>
        <zip>125480</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MSU #169</name>
      <address>
        <city>Moscow</city>
        <zip>127410</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Health&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>141021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Noginsk Central District Hospital</name>
      <address>
        <city>Moscow</city>
        <zip>142400</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital SCC RAS in Chernogolovka</name>
      <address>
        <city>Moscow</city>
        <zip>142432</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinic of the National Science Center of the Russian Academy of Sciences in Chernogolovka</name>
      <address>
        <city>Moscow</city>
        <zip>142432</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBUZ NO Pavlovsk CRH</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>600100</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Llc &quot;Healthy Little Healer&quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC &quot;Sadko&quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603074</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC Sadko</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603074</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC Dobrii doctor</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cst on St.Nizhny Novgorod Oao Rzd</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603140</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinic №7 branch 2</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603163</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GP #2</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>606039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gauz Nso Gkp #1</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Polyclinic № 2</name>
      <address>
        <city>Omsk</city>
        <zip>644009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BUZOO &quot;GP number 12&quot;</name>
      <address>
        <city>Omsk</city>
        <zip>644070</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBUZ CRB Myasnitskogo region</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>346803</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultative clinic, Regional clinical hospital #2 Rostov region</name>
      <address>
        <city>Rostov</city>
        <zip>344000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GP №16</name>
      <address>
        <city>Rostov</city>
        <zip>344000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinic GB №7</name>
      <address>
        <city>Rostov</city>
        <zip>34410</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NUZ Road Clinical Hospital at the station Rostov-Glavnii JSC &quot;Russian Railways&quot;</name>
      <address>
        <city>Rostov</city>
        <zip>346880</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gbou Vpo Pspbgmu Im. I.P. Pavlova Ministry of Health of Russia</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fsbi &quot;Szfmits Im. Va Almazova&quot; Ministry of Health of Russia</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GP №121</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197372</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-State Healthcare Institution &quot;Road Clinical Hospital at Samara Station JSC &quot;Russian Railways&quot;</name>
      <address>
        <city>Samara</city>
        <zip>443041</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gbuz Sb Sgb #10</name>
      <address>
        <city>Samara</city>
        <zip>443065</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBUZ SO &quot;Samara City Hospital 6&quot;</name>
      <address>
        <city>Samara</city>
        <zip>443074</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gbuz Co &quot;Volga Crh&quot;</name>
      <address>
        <city>Samara</city>
        <zip>443528</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center on Tupolev</name>
      <address>
        <city>Samara</city>
        <zip>445040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhigulevskaya polyclinic</name>
      <address>
        <city>Samara</city>
        <zip>445350</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City polyclinic № 2</name>
      <address>
        <city>Saratov</city>
        <zip>410005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OGBUZ Polyclinic №3</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gbuz Sk Skkkd</name>
      <address>
        <city>Stavropol'</city>
        <zip>355017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Cardiology Dispensary</name>
      <address>
        <city>Stavropol'</city>
        <zip>355026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBUZ SK &quot;Pyatigorsk GKB № 2&quot;</name>
      <address>
        <city>Stavropol'</city>
        <zip>357538</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gaus Mkdts</name>
      <address>
        <city>Tatarstan</city>
        <zip>420101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GUZ Citi hospital №13</name>
      <address>
        <city>Tula</city>
        <zip>300004</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guz Gb №13</name>
      <address>
        <city>Tula</city>
        <zip>300004</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TOKB KDC</name>
      <address>
        <city>Tula</city>
        <zip>300035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Cardiac Clinic</name>
      <address>
        <city>Tyumen</city>
        <zip>625048</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBUZ RB Polyclinic № 46</name>
      <address>
        <city>Ufa</city>
        <zip>450074</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBUZ IN city Polyclinic №1</name>
      <address>
        <city>Vladimir</city>
        <zip>600005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guz &quot;Polyclinic № 5&quot;</name>
      <address>
        <city>Volgograd</city>
        <zip>400067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volgograd Regional Clinical Cardiology Center</name>
      <address>
        <city>Volgograd</city>
        <zip>400069</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BUZ IN &quot;Voronezh city clinical polyclinic #7&quot;</name>
      <address>
        <city>Voronezh</city>
        <zip>394051</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 3, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2018</study_first_posted>
  <results_first_submitted>June 25, 2020</results_first_submitted>
  <results_first_submitted_qc>September 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 12, 2020</results_first_posted>
  <last_update_submitted>September 17, 2020</last_update_submitted>
  <last_update_submitted_qc>September 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Omacor</keyword>
  <keyword>Omega-3-acid ethyl esters</keyword>
  <keyword>patient adherence</keyword>
  <keyword>patient reported outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT03415152/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Omacor (Omega-3-acid Ethyl Esters)</title>
          <description>Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who having been prescribed Omacor for at least 6 months.&#xD;
Omacor (Omega-3-acid ethyl esters): Observational study without intervention, Omacor is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3000"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1975"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1025"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 3000 patients signed informed consent and were included in the program. Data of Visit 1 were available for 2572 (85.7%) patients, 1975 patients (65.8% of all who signed informed consent) completed the program per protocol.</population>
      <group_list>
        <group group_id="B1">
          <title>Omacor (Omega-3-acid Ethyl Esters)</title>
          <description>Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who having been prescribed Omacor for at least 6 months.&#xD;
Omacor (Omega-3-acid ethyl esters): Observational study without intervention, Omacor is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2572"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1600"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1182"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2518"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Adherence Rate at the End of the Study (Visit 3)</title>
        <description>Mean adherence rate is a ratio of the sum of days when the patient took the full prescribed dose of Omacor in the specified period to the number of days in the period.</description>
        <time_frame>6 months</time_frame>
        <population>Population of patients registered in electronic system and reported Omacor administration</population>
        <group_list>
          <group group_id="O1">
            <title>Omacor (Omega-3-acid Ethyl Esters)</title>
            <description>Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who having been prescribed Omacor for at least 6 months.&#xD;
Omacor (Omega-3-acid ethyl esters): Observational study without intervention, Omacor is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Adherence Rate at the End of the Study (Visit 3)</title>
          <description>Mean adherence rate is a ratio of the sum of days when the patient took the full prescribed dose of Omacor in the specified period to the number of days in the period.</description>
          <population>Population of patients registered in electronic system and reported Omacor administration</population>
          <units>proportion of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Score of National Questionnaire of Treatment Compliance (Edited by Fofanova T.V. et al.) at the End of the Study (Visit 3)</title>
        <description>The average score for the National questionnaire on therapy compliance for all study duration Visit 1 - Visit 3.&#xD;
The text of the National questionnaire of treatment compliance consists of five statements with four options for choice. The answer corresponding to very high compliance is estimated at 3 points, the answer corresponding to high compliance is estimated at 2 points, medium compliance - at 1 point and low compliance - 0 points. The patient can get a maximum of 15 points, a minimum of 0 points. Higher scores mean higher compliance</description>
        <time_frame>6 months</time_frame>
        <population>Population of patients attended at Visit 3 (month 6)</population>
        <group_list>
          <group group_id="O1">
            <title>Omacor (Omega-3-acid Ethyl Esters)</title>
            <description>Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who have been prescribed Omacor for at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Score of National Questionnaire of Treatment Compliance (Edited by Fofanova T.V. et al.) at the End of the Study (Visit 3)</title>
          <description>The average score for the National questionnaire on therapy compliance for all study duration Visit 1 - Visit 3.&#xD;
The text of the National questionnaire of treatment compliance consists of five statements with four options for choice. The answer corresponding to very high compliance is estimated at 3 points, the answer corresponding to high compliance is estimated at 2 points, medium compliance - at 1 point and low compliance - 0 points. The patient can get a maximum of 15 points, a minimum of 0 points. Higher scores mean higher compliance</description>
          <population>Population of patients attended at Visit 3 (month 6)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1975"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Patients Who Have Chosen Each of the Suggested Reasons for Therapy Termination</title>
        <description>The percentage of patients (%) who have chosen each of the suggested reason for therapy termination.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omacor (Omega-3-acid Ethyl Esters)</title>
            <description>Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who having been prescribed Omacor for at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients Who Have Chosen Each of the Suggested Reasons for Therapy Termination</title>
          <description>The percentage of patients (%) who have chosen each of the suggested reason for therapy termination.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2572"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse drug reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lack of efficacy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inconvenience of use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence at the pharmacy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other reason</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Average Score on Each of 8 Scales of Short Form Survey (SF)-36 Quality of Life Questionnaire at Visit 2 and Visit 3 vs. the Baseline (Visit 1)</title>
        <description>Mean difference of the average score on each of 8 scales of Short Form Survey (SF)-36 quality of life questionnaire at Visit 2 and Visit 3 versus the baseline.&#xD;
36-Item Short Form Survey (SF-36) taps eight health concepts. Each of 36 items is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively, so that a high score defines a more favorable health state.</description>
        <time_frame>3 months, 6 months</time_frame>
        <population>Population of patients registered in electronic system and reported Omacor administration</population>
        <group_list>
          <group group_id="O1">
            <title>Omacor (Omega-3-acid Ethyl Esters)</title>
            <description>Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who have been prescribed Omacor for at least 6 months Visit 2 - Visit 1 (3 months)</description>
          </group>
        </group_list>
        <measure>
          <title>The Average Score on Each of 8 Scales of Short Form Survey (SF)-36 Quality of Life Questionnaire at Visit 2 and Visit 3 vs. the Baseline (Visit 1)</title>
          <description>Mean difference of the average score on each of 8 scales of Short Form Survey (SF)-36 quality of life questionnaire at Visit 2 and Visit 3 versus the baseline.&#xD;
36-Item Short Form Survey (SF-36) taps eight health concepts. Each of 36 items is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively, so that a high score defines a more favorable health state.</description>
          <population>Population of patients registered in electronic system and reported Omacor administration</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical functioning (V2-V1,3 m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.63" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role limitations due to physical health (V2-V1,3m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.86" spread="48.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role limitations due to emotional problems (V2-V1,</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.71" spread="32.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Energy/fatique (V2-V1,3m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.81" spread="14.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional wellbeing (V2-V1,3m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.66" spread="14.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning (V2-V1,3m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.43" spread="25.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (V2-V1,3m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.43" spread="14.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health (V2-V1,3m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.14" spread="10.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical functioning (V3-V1,6m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.69" spread="10.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role limitations due to physical health (V3-V1,6m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.55" spread="43.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role limitations due to emotional problems (V3-V1,</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.18" spread="30.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Energy/fatique (V3-V1,6m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.18" spread="13.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional wellbeing (V3-V1,6m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" spread="14.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning (V3-V1,6m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.48" spread="25.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (V3-V1,6m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health (V3-V1,6m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.83" spread="12.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Lipid Profile Parameters at Visit 2 and Visit 3 vs. the Baseline (Visit 1)</title>
        <description>Mean difference of lipid profile parameters at Visit 2 and Visit 3 vs. the Baseline (Visit&#xD;
1)</description>
        <time_frame>3 months, 6 months</time_frame>
        <population>Per protocol population: patients who attended at least one follow-up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Omacor (Omega-3-acid Ethyl Esters)</title>
            <description>Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who have been prescribed Omacor for at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Lipid Profile Parameters at Visit 2 and Visit 3 vs. the Baseline (Visit 1)</title>
          <description>Mean difference of lipid profile parameters at Visit 2 and Visit 3 vs. the Baseline (Visit&#xD;
1)</description>
          <population>Per protocol population: patients who attended at least one follow-up visit.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>total serum cholesterol (TSC) (V2-V1,3m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>triglycerides (TG) (V2-V1,3m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.98" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>low-density lipoproteins (LDLP) (V2-V1,3m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>high-density lipoproteins (HDLP) (V2-V1,3m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total serum cholesterol (TSC) (V3-V1,6m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.32" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>triglycerides (TG) (V3-V1,6m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.32" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>low-density lipoproteins (LDLP) (V3-V1,6m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>high-density lipoproteins (HDLP) (V3-V1,6m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hospitalizations Due to Cardio-vascular Reasons During 6 Months of the Program</title>
        <description>Percentage of patients with hospitalizations due to cardiovascular disease</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omacor (Omega-3-acid Ethyl Esters)</title>
            <description>Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who have been prescribed Omacor for at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospitalizations Due to Cardio-vascular Reasons During 6 Months of the Program</title>
          <description>Percentage of patients with hospitalizations due to cardiovascular disease</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2572"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>The presence of hospitalizations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The absence of hospitalizations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New Cases of Stenocardia During 6 Months of the Program</title>
        <description>Percentage of patients with new cases of stenocardia</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omacor (Omega-3-acid Ethyl Esters)</title>
            <description>Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who have been prescribed Omacor for at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New Cases of Stenocardia During 6 Months of the Program</title>
          <description>Percentage of patients with new cases of stenocardia</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2572"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>The presence of new cases of angina pectoris</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The absence of new cases of angina pectoris</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Non-fatal Myocardial Infarction Cases During 6 Months of the Program</title>
        <description>Percentage of patients with non-fatal myocardial infarction cases</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omacor (Omega-3-acid Ethyl Esters)</title>
            <description>Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who have been prescribed Omacor for at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Non-fatal Myocardial Infarction Cases During 6 Months of the Program</title>
          <description>Percentage of patients with non-fatal myocardial infarction cases</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2572"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Presence of cases of non-fatal myocardial infarcti</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absence of cases of nonfatal myocardial infarctio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cases of Cardio-vascular Death During 6 Months of the Program</title>
        <description>Percentage of patients dead due to cardio-vascular death</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omacor (Omega-3-acid Ethyl Esters)</title>
            <description>Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who have been prescribed Omacor for at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cases of Cardio-vascular Death During 6 Months of the Program</title>
          <description>Percentage of patients dead due to cardio-vascular death</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2572"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Adherence Rate at Visit 2</title>
        <description>Mean adherence rate is a ratio of the sum of days when the patient took the full prescribed dose of Omacor in the specified period to the number of days in the period.</description>
        <time_frame>3 months</time_frame>
        <population>Population of patients registered in electronic system and reported Omacor administration</population>
        <group_list>
          <group group_id="O1">
            <title>Omacor (Omega-3-acid Ethyl Esters)</title>
            <description>Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who have been prescribed Omacor for at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Adherence Rate at Visit 2</title>
          <description>Mean adherence rate is a ratio of the sum of days when the patient took the full prescribed dose of Omacor in the specified period to the number of days in the period.</description>
          <population>Population of patients registered in electronic system and reported Omacor administration</population>
          <units>proportion of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Mean Adherence Rate by End of the Study (Visit 3) Versus Visit 2</title>
        <description>Mean adherence rate is a ratio of the sum of days when the patient took the full prescribed dose of Omacor in the specified period to the number of days in the period.</description>
        <time_frame>3 months, 6 months</time_frame>
        <population>Population of patients registered in electronic system and reported Omacor administration</population>
        <group_list>
          <group group_id="O1">
            <title>Omacor (Omega-3-acid Ethyl Esters)</title>
            <description>Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who have been prescribed Omacor for at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Mean Adherence Rate by End of the Study (Visit 3) Versus Visit 2</title>
          <description>Mean adherence rate is a ratio of the sum of days when the patient took the full prescribed dose of Omacor in the specified period to the number of days in the period.</description>
          <population>Population of patients registered in electronic system and reported Omacor administration</population>
          <units>proportion of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Patients With Adherence Rate &lt;0,5, 0,5-0,7, ≥0,8 at Visit 2 and Visit 3</title>
        <description>The percentage of patients with adherence rate &lt;0,5, 0,5-0,7, ≥0,8 at Visit 2 and Visit 3</description>
        <time_frame>3 months, 6 months</time_frame>
        <population>Population of patients registered in electronic system and reported Omacor administration</population>
        <group_list>
          <group group_id="O1">
            <title>Omacor (Omega-3-acid Ethyl Esters)</title>
            <description>Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who have been prescribed Omacor for at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients With Adherence Rate &lt;0,5, 0,5-0,7, ≥0,8 at Visit 2 and Visit 3</title>
          <description>The percentage of patients with adherence rate &lt;0,5, 0,5-0,7, ≥0,8 at Visit 2 and Visit 3</description>
          <population>Population of patients registered in electronic system and reported Omacor administration</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low (&lt;0.5) (V2, 3 m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate (0.5 - 0.7) (V2, 3 m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High (≥0.8) (V2, 3 m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low (&lt;0.5) (V3, 6 m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate (0.5 - 0.7) (V3, 6 m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High (≥0.8) (V3, 6 m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Score of National Questionnaire of Treatment Compliance (Edited by Fofanova T.V. et al.) [9] at Visit 1, Visit 2</title>
        <description>The average score for the National questionnaire on therapy compliance at Visit 1, Visit 2.&#xD;
The text of the National questionnaire of treatment compliance consists of five statements with four options for choice. The answer corresponding to very high compliance is estimated at 3 points, the answer corresponding to high compliance is estimated at 2 points, medium compliance - at 1 point and low compliance - 0 points. The patient can get a maximum of 15 points, a minimum of 0 points. Higher scores mean higher compliance</description>
        <time_frame>0 months, 3 months</time_frame>
        <population>Per protocol population: patients who attended at least one follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Omacor (Omega-3-acid Ethyl Esters)</title>
            <description>Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who have been prescribed Omacor for at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Score of National Questionnaire of Treatment Compliance (Edited by Fofanova T.V. et al.) [9] at Visit 1, Visit 2</title>
          <description>The average score for the National questionnaire on therapy compliance at Visit 1, Visit 2.&#xD;
The text of the National questionnaire of treatment compliance consists of five statements with four options for choice. The answer corresponding to very high compliance is estimated at 3 points, the answer corresponding to high compliance is estimated at 2 points, medium compliance - at 1 point and low compliance - 0 points. The patient can get a maximum of 15 points, a minimum of 0 points. Higher scores mean higher compliance</description>
          <population>Per protocol population: patients who attended at least one follow-up visit</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean score (V 1, 0 m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.55" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean score (V 2, 3 m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.99" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Mean Score of National Questionnaire of Treatment Compliance (Edited by Fofanova T.V. et al.) [9] at Visit 2 and Visit 3 Versus Baseline (Visit 1)</title>
        <description>The text of the National questionnaire of treatment compliance consists of five statements with four options for choice. The answer corresponding to very high compliance is estimated at 3 points, the answer corresponding to high compliance is estimated at 2 points, medium compliance - at 1 point and low compliance - 0 points. The patient can get a maximum of 15 points, a minimum of 0 points.&#xD;
Higher scores mean higher compliance</description>
        <time_frame>Baseline, 3 Months, 6 Months</time_frame>
        <population>Per protocol population: patients who attended at least one follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Omacor (Omega-3-acid Ethyl Esters)</title>
            <description>Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who have been prescribed Omacor for at least 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Mean Score of National Questionnaire of Treatment Compliance (Edited by Fofanova T.V. et al.) [9] at Visit 2 and Visit 3 Versus Baseline (Visit 1)</title>
          <description>The text of the National questionnaire of treatment compliance consists of five statements with four options for choice. The answer corresponding to very high compliance is estimated at 3 points, the answer corresponding to high compliance is estimated at 2 points, medium compliance - at 1 point and low compliance - 0 points. The patient can get a maximum of 15 points, a minimum of 0 points.&#xD;
Higher scores mean higher compliance</description>
          <population>Per protocol population: patients who attended at least one follow-up visit</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean difference (V 2-V 1, 3 m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean difference (V 3-V 1, 6 m)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months Adverse drug reactions, serious adverse drug reactions and other safety-related information are reported to sponsor from the inclusion of the patient in the program during Visit 1 until Visit 3.</time_frame>
      <desc>Adverse drug reactions (ADR) but not adverse events (AE) were collected within the study. In the case of an ADR/SADR or other safety-related data, a physician must notify the sponsor contact person within 24 hours after getting acquainted with this information.</desc>
      <group_list>
        <group group_id="E1">
          <title>Omacor (Omega-3-acid Ethyl Esters)</title>
          <description>Adult patients who signed informed consent and were included in the program with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia and who have been prescribed Omacor for at least 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3000"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3000"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 22</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3000"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3000"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3000"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Score on the &quot;G. Health&quot; of the SF-36 scale should not be taken into account due to a technical error occurred at the stage of transferring the scale to the electronic case report form and which affected the results, changing the patient's responses</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Irina Solnyshkina</name_or_title>
      <organization>Abbott Laboratories</organization>
      <phone>+7 (495) 258-42 80</phone>
      <email>irina.solnyshkina@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

